To accelerate pharmaceutical research and development and reduce risks!
PharmaPendium is a safety and drug information database for approved pharmaceuticals in the United States and Europe. In addition to allowing full-text searches of FDA advisory committee meeting minutes and EMA review reports, it also enables easy searches of toxicity and side effect information indexed by experts. It contributes to drug development through non-clinical and clinical trial planning, risk assessment of development products, and regulatory submissions.
Inquire About This Product
basic information
[Main Features] - Easily obtain drug information through keyword searches from U.S. and European pharmaceutical approval documents - A comprehensive view of non-clinical, clinical, and post-marketing safety information - Provides a variety of information including drug interactions, pharmacokinetic parameters, dosage form information, pharmacodynamics, and treatment methods [Options] - FDA Classic Collection - Pharmacokinetics Module - Metabolic Enzyme and Transporter Module - Efficacy Module
Price range
Delivery Time
Applications/Examples of results
[Usage Examples] - Non-clinical Development Department Information gathering for considerations when planning trials and confirming testing methods, referencing pharmacokinetic and metabolic data. - Clinical Development Department Assessing the necessity for additional required tests. - Planning, Development, and Strategy Department Providing decision-making materials for go/stop judgments at each development stage. - Regulatory Affairs Department Preliminary research for the preparation of application documents. - Formulation Department
Company information
Elsevier was founded in 1880 as a scholarly publishing company in Rotterdam, Netherlands, specializing in information services related to science, technology, and medicine. It provides access to over one billion research papers used by researchers, engineers, students, healthcare professionals, and information specialists, including fields where more than 99% of Nobel Prize winners have published since 2000. By offering global information and innovative tools, it assists customers in making critical decisions, enhancing productivity, and improving research outcomes, contributing to advancements in science and medicine. Through collaboration with experts worldwide, it develops solutions that drive discoveries and innovations, providing various information services tailored to needs, and promoting research and development with the necessary information and technology to enhance decision-making regarding new scientific discoveries and business directions, as well as improving the accuracy of risk assessments.
![[Information] Elsevier Japan K.K. Product List for Businesses](https://image.mono.ipros.com/public/product/image/35c/2000490133/IPROS9194000127241306554.png?w=280&h=280)
